The life science industry is expected to be a major growth sector in Australia over the coming years with global pharmaceutical companies expanding their production capabilities across R&D, manufacturing, and distribution.
This expansion, backed by Federal Government support is set to solidify Australia’s sovereign capability as the COVID-19 pandemic prompts a greater focus on this sector.
So how will this impact occupier and investment activity growth within commercial property and where do we see this sector in ten years?
In a Podcast episode of Talking Property, Sass J-Baleh Head of Industrial & Logistics Research at CBRE sits down with Julie Phillips, CEO and Director of BioDiem, Jack Walters Head of Industrial Transactions at Charter Hall and Chris O’Brien Executive Director, Capital Markets, Industrial & Logistics at CBRE.
Together, they take a closer a look at the Australian life sciences sector from pharmaceutical manufacturing and demand for life science assets, through to the types of investor groups showing interest, major transactions and their predictions for industry growth over the next decade.
Check it out here.